HIV/HCV co-infection: Histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: A review article

Liver International

Volumn 27, Issue 5, 2007, Pages 598-606

  Petrovic, Lydia M ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

HAART; HIV HCVco infection; Liverbiopsy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CYCLOSPORIN; DIDANOSINE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 8; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ALCOHOLISM; ANTIVIRAL ACTIVITY; AUTOIMMUNITY; CELLULAR IMMUNITY; DIABETES MELLITUS; DISEASE COURSE; DRUG ABUSE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EOSINOPHILIA; FATTY LIVER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER METABOLISM; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PANCREATITIS; PROTEIN EXPRESSION; RECURRENT INFECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SUPERINFECTION; VIRUS REPLICATION; WEIGHT REDUCTION;

ANTI-RETROVIRAL AGENTS; BIOPSY; CYTOKINES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 34547115207     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01478.x     Document Type: Review

References (66)

1. Jones R, Dunning J, Nelson M. HIV and hepatitis C co-infection. Int J Clin Pract 2005; 59: 1082-92.
2. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol 2006; 44: 525-7.
3. Leen CLS. Hepatitis C and HIV co-infection. Int J STD & AIDS 2004; 15: 289-95.
4. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parentally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
5. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197-07.
6. Sulkowski M, Thomas D. HAART and the HCV-infected liver: Friend or foe? J Hepatol 2004; 41: 181-4.
7. Mehta S, Thomas D, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C co-infection. Hepatology 2005; 41: 123-31.
8. Marine-Barjoan E, Saint-Paul MC, Pardier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/ hepatitis C virus co-infected patients. AIDS 2004; 18: 2163-70.
9. Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006; 44: 528-34.
10. Greub G, Ledergerber B, Battagay M, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C co-infection: The Swiss HIV cohort study. Lancet 2000; 356: 1800-5.
11. Garcia-Samaniego J, Rodiguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.
12. Garcia-Samaniego J, Soriano V, Castilla J, et al. Influence of hepatitis C virus genotype and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterology 1997; 92: 1130-4.
13. Benhamou Y, Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
14. Mohsen AH, Eastbrook PJ, Taylor C, Portmann B, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-40.
15. Bonacini M, Govandarajan S, Blatt LM, et al. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Virol Hepatol 1999; 6: 203-8.
16. Canchis PW, Yee H, Fiel IM, et al. Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-co-infected patients. J AIDS 2004; 37: 1125-31.
17. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. J Hepatol 2005; 43: 78-84.
18. Tolan DJ, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. N Engl J Med 2001; 345: 1781.
19. Macias J, Japon MA, Saez C, Palacios RB, et al. Increased hepatocyte Fas expression and apoptosis in HIV and hepatitis C virus co-infection. J Infect Dis 2005; 192: 1566-76.
20. Balasubramanian A, Ramesh K, Gaju K, Groopman JE. Hepatitis C virus and IV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem 2003; 278: 35755-766.
21. Marks K, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients co-infected with HIV and hepatitis C virus. J Infect Dis 2005; 192: 1943-9.
22. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C co-infection: Prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42: 310-6.
23. Mcgovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-serpositive patients. Clin Infect Dis 2006; 43: 365-72.
24. Winnock M, Salmon-Ceron D, Dabis F, Chene G. Interaction between HIV-1 and HCV infections: Towards a new entity? Journal of Antimicrobial Chemotherapy 2004; 53: 936-46.
25. Clouston AD, Jonsson JR, Purdie DM. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34: 314-20.
26. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
27. Blackard JT, Komurian-Pradel F, Perret M, et al. Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection. J Med Virol 2006; 78: 202-7.
28. Garba ML, Pilcher CD, Bingham AL, et al. HIV antigens can induce TGF-β1-producing immunoregulatory CD8+ T cells. J Immunol 2002; 168: 2247-54.
29. Harcourt G, Gomperts E, Donfield S, et al. Profound loss of HCV-specific interferon-gamma secreting CD4+ T cells in HIV/HCV co-infected patients. Gut 2006; 55: 148-7.
30. Sanchez-Conde M, Berenguer J, Miralles P, et al. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine transaminase. Clin Invest Dis 2006; 43: 640-4.
31. Geller SA, Petrovic LM., In: Biopsy Interpretation of the Liver. Lippincott: Williams and Wilkins, 2003; 242-68.
32. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
33. Batts KP, Ludwig J. Chronic hepatitis: An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
34. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINVIR and DOSVIRC groups. Lancet 1997; 34: 825-32.
35. Lefkowitch JH. Pathology of AIDS-related. Dig Dis 1994; 12: 321-30.
36. Cappell MS. Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am J Gastroenterol 1991; 86: 1-15.
37. Bach N, Theise ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Sem Liv Dis 1992; 19: 252-8.
38. Lichterfeld M, Haas S, Fischer HP, et al. Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease. J Gastroenterol Hepatol 2005; 20: 739-45.
39. Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997; 430: 271-7.
40. Allory Y, Charlotte F, Benhamou Y, et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case control study. Hum Pathol 2000; 31: 69-74.
41. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIV/HCV co-infected patients: Analysis of risk factors. AIDS 2006; 20: 525-31.
42. Scoazec JY, Feldman G. Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus. Hepatology 1990; 12: 505-10.
43. Housset C, Lamas E, Courgnaud V, et al. Presence of HIV-1 in human parenchymal and non-parenchymal cells in vivo. J Hepatol 1993; 19: 252-8.
44. Woitas RP, Stoschus B, Terjung B, Vogel M, et al. Hepatitis C-associated autoimmunity in patients coinfected with HIV. Liver Int 2005; 25: 1114-21.
45. Rullier A, Trimoulet P, Neau D, et al. Fibrosis is worse in HIV/HCV patients with low-level of immunosuppression refrred for HCV treatment than in HCV-matched patients. Hum Pathol 2004; 35: 1088-94.
46. Maier I, Wu GY. Hepatitis C and HIV co-infection; a review. World J Gastroenterol 2002; 15;8: 577-9.
47. Kelleher TB, Afdhal N. Assessment of liver fibrosis in co-infected patients. J Hepatol 2006; 44: S126-31.
48. Macias J, Castellano V, Merchanta N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS 2004; 18: 767-74.
49. Verma S. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: Fact or fiction? J Antimicrob Chemotherapy 2006; 58: 496-501.
50. Brau N, Salavatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
51. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochemie 2005; 87: 65-71.
52. Lapadula G, Torti C, Paraninfo G, Castelnuovo F, et al. Influence of hepatitis C genotype on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006; 11: 521-7.
53. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
54. Nunez M, Rios P, Martin-Carbonero L, et al. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Syndr 2002; 30: 65-8.
55. Torti C, Lapadula G, Puoti M, Casari S, et al. Influence of genotype 3 hepatitis C co-infection on liver enzyme elevation in HIV-1 positive patients after commencement of new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr 2006; 41: 180-5.
56. Yoo T, Donfield S, Lail A, et al. Effect of hepatitis C virus genotype on HCV disease. J Infect Dis 2005; 191: 1-3.
57. Soriano V, Sulkowksi M, Bergen C, et al. Care of patients with chronic hepatitis C and HIV coinfection; recommendation for from the HIV/HCV International Panel. AIDS 2002; 16: 813-24.
58. Brunt EM, Janney CG, DiBisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions. Am J Gastroenterology 1999; 94: 2467-74.
59. Quereda C, Moreno S, Moreno I, et al. The role of liver biopsy in the management of chronic hepatitis C in patients infected with the human immunodeficiency virus. Hum Pathol 2004; 35: 1083-7.
60. Aranzabal L, Casado JL, Moyra J, et al. Influence of liver fibrosis on highly active antiretroviral therapy associated hepatotoxicty in patients with HIV and hepatitis C virus co-infection. Clin Infect Dis 2005; 40: 588-93.
61. Verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients. Clin Invest Dis 2006; 42: 252-70.
62. Bonacini M. Management issues in patients co-infected with hepatitis C and HIV. AIDS Read 2002; 12: 19-21.
63. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C and B virus infection. JAMA 2000; 283: 74-80.
64. Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72: 177-81.
65. Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patients in the era of highly active antiretroviral therapy. AIDS 2001; 15: 291-2.
66. Neff GW, Bonham A, Tsakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-47.